-
AI & Machine Learning in Biotechnology3 months ago
Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition
Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the New Jersey Big Pharma.Read More
-
Fierce Biotech3 months ago
Sarepta’s big bet on Arrowhead’s siRNA assets yields early data
Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its decision to bet big on Arrowhead...
-
Uncategorized3 months agoStudy supports Treg enhancement as dementia treatment
A research study led by Dr Alireza Faridar and Dr Stanley Appel at the Houston Methodist Neurological Institute has demonstrated the involvement of the peripheral immune...
-
STAT News – Biotech3 months agoSTAT+: How an outsider crept into Eli Lilly’s top ranks — and plans to drive its business forward
Everything changed with a white envelope. On Dec. 20, 2018, Jacob Van Naarden, the chief operating officer of a biotech called Loxo Oncology, and his boss,...
-
STAT News – Biotech3 months agoOpinion: The U.S. needs to be worried about Iranian biological materials
The war with Iran has focused the world’s attention on nuclear weapons and oil. Those risks are real. But there is a third category of danger...
-
STAT News – Biotech3 months agoSTAT+: Qualified Health raises $125 million, as it helps more health systems build and manage AI tools
It was 2023. ChatGPT had been released less than five months earlier. Justin Norden was sitting around a table with a dozen health care leaders at...
-
STAT News – Biotech3 months agoOpinion: Emergency departments are not equipped to help patients with dementia
I recently spent a long afternoon hiding from the nurse in the emergency room of a prestigious hospital. My sister and I were there with my...
-
Fierce Biotech3 months ago
Novo Nordisk prepares to go global as triple-G prospect passes midphase diabetes test in China
Novo Nordisk and its Chinese partner have reported another midphase win for their triple G candidate, sharing diabetes data to add to the momentum generated by...
-
Fierce Biotech3 months ago
BrightGene’s oral dual agonist sees up to 8% weight loss at 8 weeks in slice of early data
China’s BrightGene has served up a slice of early-stage data to remind everyone that it has a horse in the oral obesity race.
-
STAT News – Biotech3 months agoFederal vaccine adviser departs ACIP
WASHINGTON — Robert Malone, an outspoken medical doctor and ally of health secretary Robert F. Kennedy Jr., is stepping away from a panel of federal vaccine...
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
